Western Oncolytics is dedicated to bringing its cancer immunotherapies to patients across the globe.

In 2016, Western Oncolytics entered into an R&D collaboration, license, and option agreement with Pfizer for its lead program, WO-12.

Outside of WO-12, Western Oncolytics retains full global rights to its VET platform and individual transgene programs. If you are interested in collaborating with us, please reach out to partnering@westernoncolytics.com.